Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
$2.04
-$0.22(-8.53%)
At close: 4:00 PM EST
$2.04
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.61 - $3.65
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$371.36M
Enterprise Value$189.31M
Total Cash (Recent Filing)$182.53M
Total Debt (Recent Filing)$477.00K
Price to Earnings (P/E)―
Beta2.44
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding182,040,940
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.86
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$9.33Price Target Upside357.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Alzheimer's Agitation EfficacyA prespecified analysis indicated NMRA-511 reduced agitation in Alzheimer's patients with elevated anxiety and demonstrated favorable tolerability that could permit higher dosing and a safer, non-sedative treatment option compared with existing therapies.
Pharmacokinetics And Dosing FlexibilityNMRA-898 showed a predictable pharmacokinetic profile and a long half-life that support once-daily dosing and provide flexible evidence of target engagement for its schizophrenia program.
Pipeline Diversification And Analyst OutlookAnalyst's upgrade to Outperform reflects a view that multiple distinct development programs increase the chances of clinical success and improve the company's risk/reward profile given low market expectations.
Bears Say
Program Pause And Trial RiskPausing development of NMRA-861 and high risk associated with the KOASTAL trials add uncertainty about future pipeline contributions and support a cautious market view.
Regulatory Approval DependencyRegulatory approval plans hinge on the success of at least one pivotal KOASTAL study, creating outcome-dependent risk that could impede approval if trials fail to meet endpoints.
Toxicology-related DelaysUnexpected adverse findings in a rat toxicology study forced repeat testing and delayed the start of NMRA-215 human trials, postponing potential weight-loss and cardiac biomarker readouts and creating an investor overhang.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $371.36M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Mar 30, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.325 by -$0.025.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 182,040,940 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.325. Following the earnings report the stock price went down -17.167%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (357.35% Upside)
$9.33 (357.35% Upside)
Hedge Fund Trend
Increased
By 179.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $77.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-113.81%
Trailing 12-Months
Asset Growth
-49.56%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$9.33
▲(357.35% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
65.70% Insiders
3.31% Mutual Funds
19.41% Other Institutional Investors
8.40% Public Companies and
Individual Investors